目的 探究利巴韋林聯(lián)合聚乙二醇干擾素α-2a在治療慢性丙型肝炎中的臨床療效。方法 選取2010年6月—2012年6月在西安市唐都醫(yī)院進(jìn)行治療的慢性丙型肝炎患者100例，隨機(jī)分成對(duì)照組（50例）和治療組（50例），在常規(guī)治療的基礎(chǔ)上，對(duì)照組口服利巴韋林片，0.3 g/次，3次/d，同時(shí)皮下或肌肉注射重組人干擾素α2a注射液，500萬IU/次，每周3次。治療組皮下注射聚乙二醇干擾素α-2a注射液，180 μg/次，每周1次，利巴韋林的用法用量同對(duì)照組。兩組均治療48周。治療結(jié)束后比較兩組患者血清丙氨酸轉(zhuǎn)氨酶（ALT）復(fù)常率、HCV RNA轉(zhuǎn)陰率及不良反應(yīng)。結(jié)果 治療后，治療組患者治療結(jié)束時(shí)病毒學(xué)應(yīng)答（ETVR）和持續(xù)病毒學(xué)應(yīng)答（SVR）比例分別為82%、76%，均明顯高于對(duì)照組的64%、50%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療24、48周及治療后24周，治療組HCV RNA轉(zhuǎn)陰率和ALT復(fù)常率均明顯高于對(duì)照組，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 利巴韋林聯(lián)合聚乙二醇干擾素α-2a治療慢性丙肝有較好的臨床療效，可以在臨床推廣應(yīng)用。

Objective To explore the therapeutic effect of ribavirin combined with polyethylene glycol interferon α-2a in the treatment of chronic hepatitis C. Methods Patients with chronic hepatitis C (100 cases) in Xi'an Tangdu Hospital from June 2010 to June 2012 were randomly divided into treatment (50 cases) and control (50 cases) groups. The patients in the control group were po administered with Ribavirin Tablet, 0.3 g/time, for three times daily on the basis of routine therapy, and at the same time, they were im or sc administered with Recombinant Interferon α-2a Injection, 5×10⁶ U/time, for three times a week. The patients in the treatment group were sc administered with Polyethylene Glycol Interferon α-2a Injection, 180 μg/time, once a week, at the same time, ribavirin at dosage was used as the same in the control group. The patients in two groups were treated for 48 weeks. The recovery rate of ALT, RNA negative rate of HCV, and adverse reactions were compared after treatment. Results After treatment, the proportions of ETVR and SVR were 82% and 76%, respectively, which were significantly higher than those of the control group (64% and 50%), and they were statistically significant (P < 0.05). The recovery rate of ALT and RNA negative rate of HCV 24 and 48 weeks after treatment in the treatment group were significantly higher than those in the control group (P < 0.05). Conclusion Ribavirin combined with polyethylene glycol interferon α-2a has an accurate curative effect on chronic hepatitis C, which could be used in clinic.